Effect of K-MAP on platelet hyperaggregation in diabetic mellitus patients

K-MAP (p-aminobenzoic acid-N-D-mannoside sodium salt) shows an antiplatelet action by altering prostaglandin metabolism. This study was conducted to elucidate the effect of K-MAP on platelet hyperaggregation in diabetes mellitus (DM) patients.K-MAP (900mg/day) was daily administered for 12 weeks in 39 patients with DM (57.0±11.8 years of age, male 23, female 16). Platelet aggregation β-thromboglobulin (β-TG), platelet 4 (PF-4), plasma 6-keto PGF1α, plasma TXB2, fibrinogen and serum lipids were measured on every 4 weeks.The obtained results were as follows: 1) Platelet hyperaggregation was observed in 20 patients. K-MAP reduced the hyperaggregation to normal level in 13 patients. 2) A linear relationship was found with a high degree of correlation (r=0.925) between β-TG and PF-4. β-TG and PF-4 were significantly decreased by K-MAP treatment. 3) The low level of 6-keto PGF1α was increased, while the high level of TXB2 decreased by K-MAP treatment. 4) The increased fibrinogen and abnormal serum lipids levels were improved to normal levels by K-MAP treatment. 5) No side effect was detected during administration of K-MAP.These results support the usefulness of clinical application of K-MAP as a drug preventing from diabetic vascular complications.